Nanotechnology Now - Press Release: Drug - Device Combinations Are an Emerging Part of the Drug Delivery Systems Market: companiesandmarkets.com

Home > Press > Drug - Device Combinations Are an Emerging Part of the Drug Delivery Systems Market: companiesandmarkets.com

Abstract:
- Drug-device combinations offer high levels of efficacy, fewer side effects and sustained drug release
- Miniaturization is a key trend in drug delivery and medical devices
- Further biomaterials R&D required to ensure suitability of drug ‘coatings'

Drug - Device Combinations Are an Emerging Part of the Drug Delivery Systems Market: companiesandmarkets.com

London, UK | Posted on August 31st, 2011

For serious conditions, treatment regimes using combination drug-devices are proving to be effective in enhancing patient lifespan according to a new research report available on companiesandmarkets.com. These techniques have been shown to reduce the level of toxicity within organs, as well as lengthening patients' lives.

Combination Devices - Application Landscape
www.companiesandmarkets.com/Market-Report/combination-devices-application-landscape-684509.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2

Combination drug-devices are revolutionising the manner in which drugs are administered to patients: their targeted approach reduces unwanted side effects and allows for a higher dose of the drug to be delivered to the appropriate site.

Developed using biomaterials, nanotechnology, photodynamic therapy and many other techniques, drug-device combinations are an emerging part of the drug delivery systems market. Support has grown for this drug delivery approach following promising clinical research, and major developments in the associated technologies. Major advances in the field of imaging technologies have made it easier for researchers to observe the combination devices drug delivery process, to determine the feasibility and efficacy of the technique.

Using drug-device combinations, cancer treatments such as docetaxel can now be carried through the body within silica nanorattles and released over time, and at an appropriate pH. The focus on cancer drugs stems from the fact that a two-pronged approach must be taken to address the heterogeneity of the tumor itself, as well as its adaptive resistance. Drug-device combination therapies are proving plausible methods of addressing both requirements.

Spin-off companies and technology licensing are expected next steps within the market, as commercialization is an expensive process. Smaller companies and research groups are likely to pursue collaborations or partnerships with pharmaceutical and medical device companies.

The 68 page, June 2011 report, provides the reader with a detailed insight into the combination drug devices market. It includes information on key market players, products, patents, technology overviews and opportunity evaluation. Three key markets are discussed in detail:diagnostic tools, bacteriophages and antibiotics.

The report also includes information and statistics on healthcare expenditure, cancer and cardiovascular disease incidence and pharmaceutical expenditure on R&D.

####

For more information, please click here

Contacts:
Paul Chapman
Press Office
Companies & Markets

London (UK): +44 (0) 203 086 8600

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: